Imatinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19141 publications

The Goldilocks state of transcriptional readthrough for chimeric splicing.

The Goldilocks state of transcriptional readthrough for chimeric splicing.

Journal: Transcription

Published: April 10, 2026

Simulation of Imatinib Pharmacokinetics in pregnant women with chronic myeloid leukemia in the third trimester.

Simulation of Imatinib Pharmacokinetics in pregnant women with chronic myeloid leukemia in the third trimester.

Journal: European journal of clinical pharmacology

Published: March 31, 2026

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Journal: Pharmacological research

Published: March 31, 2026

Economic evaluation of ponatinib vs reference and generic imatinib in front-line management of philadelphia chromosome-positive acute lymphoblastic leukemia: A value dilemma.

Economic evaluation of ponatinib vs reference and generic imatinib in front-line management of philadelphia chromosome-positive acute lymphoblastic leukemia: A value dilemma.

Journal: Journal of managed care & specialty pharmacy

Published: March 26, 2026

The activity, selectivity and pharmacological profile of imatinib derivates against Trypanosoma cruzi.

The activity, selectivity and pharmacological profile of imatinib derivates against Trypanosoma cruzi.

Journal: Parasitology

Published: March 25, 2026

Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations.

Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations.

Journal: Expert opinion on pharmacotherapy

Published: March 24, 2026

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib.

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib.

Journal: Science advances

Published: March 20, 2026

Dual-specificity phosphatase 21 enhances the sensitivity of imatinib-resistant chronic myeloid leukemia cells to ponatinib through GATA-1-mediated erythroid differentiation.

Dual-specificity phosphatase 21 enhances the sensitivity of imatinib-resistant chronic myeloid leukemia cells to ponatinib through GATA-1-mediated erythroid differentiation.

Journal: Biochemical and biophysical research communications

Published: March 16, 2026

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.

Journal: Journal of medicinal chemistry

Published: March 10, 2026

Painful fissured plaques on the palms and soles in a patient with chronic myeloid leukemia.

Painful fissured plaques on the palms and soles in a patient with chronic myeloid leukemia.

Journal: JAAD case reports

Published: March 09, 2026

Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center.

Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center.

Journal: International journal of molecular sciences

Published: March 05, 2026

Key points in selecting first-line therapy for chronic myeloid leukemia

Key points in selecting first-line therapy for chronic myeloid leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 04, 2026

Showing 1-12 of 19,141

Last Updated: 04/28/2026